- $7.86bn
- $3.06bn
- $124.80m
- 41
- 17
- 44
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.51 | ||
| Price to Tang. Book | 1.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 155.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.15% | ||
| Return on Equity | -8.68% | ||
| Operating Margin | -1921.95% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 67.69 | 23.8 | 55.29 | 61.28 | 124.8 | 94.35 | 28.34 | 16.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.
Directors
- Vivek Ramaswamy CHM (36)
- Eric Venker PRE (35)
- Mayukh Sukhatme PRE (46)
- Matthew Gline CEO (37)
- Richard Pulik CFO (42)
- Rakhi Kumar CAO (41)
- Masayo Tada DRC (76)
- Daniel Gold IND (53)
- Andrew Lo IND (61)
- Patrick Machado IND (57)
- Keith Manchester IND (52)
- James Momtazee IND (49)
- Ilan Oren IND (37)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 7th, 2014
- Public Since
- December 3rd, 2020
- No. of Shareholders
- 70
- No. of Employees
- 845
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 713,549,458
- Address
- 11-12 St. James's Square, LONDON, SW1Y4LB
- Web
- http://roivant.com/
- Phone
- +44 2074003347
- Auditors
- Ernst & Young LLP
Upcoming Events for ROIV
Q1 2025 Roivant Sciences Ltd Earnings Release
Roivant Sciences Ltd Annual Shareholders Meeting
Similar to ROIV
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Roivant Sciences share price?
As of Today at 22:57 UTC, shares in Roivant Sciences are trading at $11.01. This share price information is delayed by 15 minutes.
How has the Roivant Sciences share price performed this year?
Shares in Roivant Sciences last closed at $11.01 and the price had moved by +1.19% over the past 365 days. In terms of relative price strength the Roivant Sciences share price has underperformed the S&P500 Index by -6.59% over the past year.
What are the analyst and broker recommendations for Roivant Sciences?
The overall consensus recommendation for Roivant Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Roivant Sciences dividend yield?
Roivant Sciences does not currently pay a dividend.
Does Roivant Sciences pay a dividend?
Roivant Sciences does not currently pay a dividend.
When does Roivant Sciences next pay dividends?
Roivant Sciences does not currently pay a dividend.
How do I buy Roivant Sciences shares?
To buy shares in Roivant Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Roivant Sciences?
As of the previous close price of $11.01, shares in Roivant Sciences had a market capitalisation of $7.86bn.
Where are Roivant Sciences shares listed?
Here are the trading details for Roivant Sciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ROIV
What kind of share is Roivant Sciences?
Based on an overall assessment of its quality, value and momentum Roivant Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Roivant Sciences share price forecast for 2025?
The analyst consensus target price for shares in Roivant Sciences is $16.86. That is 53.13% above the last closing price of $11.01.
Analysts covering Roivant Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.35 for the next financial year.
Find out moreWhat is the trend in the Roivant Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Roivant Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -2.65%.
As of the last closing price of $11.01, shares in Roivant Sciences were trading -2.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Roivant Sciences PE Ratio?
The Roivant Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Roivant Sciences?
Roivant Sciences' management team is headed by:
- Vivek Ramaswamy - CHM
- Eric Venker - PRE
- Mayukh Sukhatme - PRE
- Matthew Gline - CEO
- Richard Pulik - CFO
- Rakhi Kumar - CAO
- Masayo Tada - DRC
- Daniel Gold - IND
- Andrew Lo - IND
- Patrick Machado - IND
- Keith Manchester - IND
- James Momtazee - IND
- Ilan Oren - IND